Stepan Havranek1, Ales Linhart, Zuzana Urbanova, Uma Ramaswami. 1. Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
Abstract
OBJECTIVE: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes. METHODS: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5-16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls. RESULTS: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122-177) vs. 122 (82-165) ms; p < 0.0001]. CONCLUSIONS: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.
OBJECTIVE: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes. METHODS: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5-16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls. RESULTS: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122-177) vs. 122 (82-165) ms; p < 0.0001]. CONCLUSIONS: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.
Authors: Christoph Kampmann; Ales Linhart; Frank Baehner; Tomas Palecek; Christiane M Wiethoff; Elke Miebach; Catharina Whybra; Andreas Gal; Jan Bultas; Michael Beck Journal: Int J Cardiol Date: 2008-06-24 Impact factor: 4.164
Authors: Frédéric Barbey; Salah D Qanadli; Christoph Juli; Noureddine Brakch; Tomás Palacek; Elena Rizzo; Xavier Jeanrenaud; Boris Eckhardt; Ales Linhart Journal: Eur Heart J Date: 2009-10-21 Impact factor: 29.983
Authors: Manesh R Patel; Franco Cecchi; Marta Cizmarik; Ilkka Kantola; Ales Linhart; Kathy Nicholls; Jörg Strotmann; Jose Tallaj; Thi Chien Tran; Michael L West; Dana Beitner-Johnson; Ademola Abiose Journal: J Am Coll Cardiol Date: 2011-03-01 Impact factor: 24.094
Authors: A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke Journal: Lancet Date: 2009-12-12 Impact factor: 79.321
Authors: Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann Journal: Circulation Date: 2009-01-19 Impact factor: 29.690
Authors: M Cybulla; K Walter; H P Neumann; U Widmer; M Schärer; G Sunder-Plassmann; T Jansen; A Rolfs; M Beck Journal: Dtsch Med Wochenschr Date: 2007-07-05 Impact factor: 0.628
Authors: P M Elliott; H Kindler; J S Shah; B Sachdev; O E Rimoldi; R Thaman; M T Tome; W J McKenna; P Lee; P G Camici Journal: Heart Date: 2005-08-05 Impact factor: 5.994
Authors: Maarten Arends; Christoph Wanner; Derralynn Hughes; Atul Mehta; Daniel Oder; Oliver T Watkinson; Perry M Elliott; Gabor E Linthorst; Frits A Wijburg; Marieke Biegstraaten; Carla E Hollak Journal: J Am Soc Nephrol Date: 2016-12-15 Impact factor: 10.121
Authors: Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin Journal: Genet Med Date: 2014-09-18 Impact factor: 8.822
Authors: Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto Journal: J Bras Nefrol Date: 2022 Apr-Jun
Authors: Frits A Wijburg; Bernard Bénichou; Daniel G Bichet; Lorne A Clarke; Gabriela Dostalova; Alejandro Fainboim; Andreas Fellgiebel; Cassiano Forcelini; Kristina An Haack; Robert J Hopkin; Michael Mauer; Behzad Najafian; C Ronald Scott; Suma P Shankar; Beth L Thurberg; Camilla Tøndel; Anna Tylki-Szymańska; Uma Ramaswami Journal: PLoS One Date: 2015-05-08 Impact factor: 3.240
Authors: Dominique P Germain; Eva Brand; Alessandro Burlina; Franco Cecchi; Scott C Garman; Judy Kempf; Dawn A Laney; Aleš Linhart; László Maródi; Kathy Nicholls; Alberto Ortiz; Federico Pieruzzi; Suma P Shankar; Stephen Waldek; Christoph Wanner; Ana Jovanovic Journal: Mol Genet Genomic Med Date: 2018-04-12 Impact factor: 2.183